On April 7, 2021 ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health, reported that Pierre Belichard, CEO, will present an overview of the Company and take part in 1-on-1 meetings with institutional investors at the following conferences (Press release, Enterome, APR 7, 2021, View Source;utm_medium=rss&utm_campaign=enterome-to-present-at-upcoming-conferences [SID1234577684]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
European Biotech Investor Days: April 7-8
Jefferies Microbiome-based therapeutics Summit: April 22
Jefferies Virtual Healthcare Conference: June 1-3
Enterome’s CBO, Anne Dagallier, will participate and take part in 1-on-1 meetings with potential business partners at the following conferences:
Digestive Disease Week (DDW): May 21-23
BIO International Convention: June 14-18